PARP1 and ovarian cancer: Preliminary data showed that PARPi or PARP depletion has a radiosensitization effect to enhance the efficacy of radiotherapy in ovarian cancer, breast cancer, cholangiocarcinoma, and soft tissue sarcoma.124, 125, 126, 127 The addition of DNA methyltransferase inhibitors (DNMTis) to PARPi could further improve the response in NSCLC cells to IR in vitro and in vivo.126